NASDAQ:ANIX Anixa Biosciences (ANIX) Stock Price, News & Analysis → DON’T buy gold until you read this (From Sasco Gold LLC) (Ad) Free ANIX Stock Alerts $2.67 +0.12 (+4.71%) (As of 06/10/2024 ET) Add Compare Share Share Today's Range$2.55▼$2.7050-Day Range$2.36▼$3.2852-Week Range$2.21▼$5.13Volume100,140 shsAverage Volume127,783 shsMarket Capitalization$85.47 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Anixa Biosciences alerts: Email Address Anixa Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside162.2% Upside$7.00 Price TargetShort InterestHealthy1.82% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.35Based on 14 Articles This WeekInsider TradingAcquiring Shares$284,439 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.44) to ($0.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.10 out of 5 starsMedical Sector320th out of 904 stocksPharmaceutical Preparations Industry146th out of 427 stocks 3.5 Analyst's Opinion Consensus RatingAnixa Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAnixa Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Anixa Biosciences' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.82% of the float of Anixa Biosciences has been sold short.Short Interest Ratio / Days to CoverAnixa Biosciences has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Anixa Biosciences has recently decreased by 12.31%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAnixa Biosciences does not currently pay a dividend.Dividend GrowthAnixa Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ANIX. Previous Next 4.1 News and Social Media Coverage News SentimentAnixa Biosciences has a news sentiment score of 1.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Anixa Biosciences this week, compared to 2 articles on an average week.Search Interest14 people have searched for ANIX on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.MarketBeat Follows9 people have added Anixa Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 125% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Anixa Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $284,439.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders22.60% of the stock of Anixa Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 29.13% of the stock of Anixa Biosciences is held by institutions.Read more about Anixa Biosciences' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Anixa Biosciences are expected to decrease in the coming year, from ($0.44) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anixa Biosciences is -7.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anixa Biosciences is -7.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnixa Biosciences has a P/B Ratio of 3.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Anixa Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Sasco Gold LLCDON’T buy gold until you read thisIf you're an American who understands that your money is rotting away as you read this email… Then this is for YOU. 99% of people are buying gold the wrong way.Reserve your seat here. About Anixa Biosciences Stock (NASDAQ:ANIX)Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Read More ANIX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANIX Stock News HeadlinesJune 11 at 5:13 AM | insidertrades.comInsider Buying: Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Purchases 10,738 Shares of StockJune 8 at 9:00 AM | insidertrades.comInsider Buying: Anixa Biosciences, Inc. (NASDAQ:ANIX) CFO Acquires 6,250 Shares of StockJune 11 at 3:36 AM | americanbankingnews.comAnixa Biosciences (NASDAQ:ANIX) Price Target Lowered to $7.00 at HC WainwrightJune 10 at 6:34 AM | americanbankingnews.comInsider Buying: Anixa Biosciences, Inc. (NASDAQ:ANIX) CFO Buys 6,250 Shares of StockJune 10 at 5:46 AM | americanbankingnews.comAnixa Biosciences, Inc. (NASDAQ:ANIX) CEO Purchases $60,250.00 in StockJune 7, 2024 | americanbankingnews.comAnixa Biosciences (NASDAQ:ANIX) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPSJune 7, 2024 | americanbankingnews.comAnixa Biosciences (NASDAQ:ANIX) Announces Earnings ResultsMay 28, 2024 | investorplace.com7 Penny Biotech Stocks to Triple Your InvestmentMay 21, 2024 | finanznachrichten.deAnixa Biosciences, Inc.: Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical TrialMay 21, 2024 | prnewswire.comAnixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical TrialMay 8, 2024 | finanznachrichten.deAnixa Biosciences, Inc.: Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer VaccinesMay 8, 2024 | msn.comAnixa Biosciences enters JV with Cleveland Clinic for additional cancer vaccinesMay 8, 2024 | markets.businessinsider.comAnixa Inks Joint Development Agreement With Cleveland Clinic To Develop Novel Cancer VaccinesMay 8, 2024 | prnewswire.comAnixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer VaccinesMay 6, 2024 | prnewswire.comAnixa Biosciences CEO Featured on "Target: Cancer Podcast" by Oncologist Dr. Sanjay JunejaApril 30, 2024 | prnewswire.comAnixa Biosciences to Participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024April 18, 2024 | finance.yahoo.comAnixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory BoardMarch 16, 2024 | finance.yahoo.comANIX Apr 2024 2.500 putMarch 16, 2024 | finance.yahoo.comANIX Apr 2024 7.500 callMarch 14, 2024 | prnewswire.comAnixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested PartiesMarch 12, 2024 | benzinga.comRecap: Anixa Biosciences Q1 EarningsMarch 11, 2024 | prnewswire.comAnixa Biosciences Announces Presentation at 24th Annual World Vaccine CongressFebruary 22, 2024 | benzinga.comAnixa Biosciences Stock (NASDAQ:ANIX) Insider TradesFebruary 21, 2024 | investing.comAnixa Biosciences Inc (ANIX)February 17, 2024 | finance.yahoo.comWe Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business GrowthSee More Headlines Receive ANIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anixa Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings6/04/2024Today6/11/2024Next Earnings (Estimated)9/04/2024Fiscal Year End10/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ANIX CUSIPN/A CIK715446 Webwww.anixa.com Phone(408) 708-9808Fax631-549-5974Employees4Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+162.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,810,000.00 Net MarginsN/A Pretax Margin-5,174.29% Return on Equity-49.27% Return on Assets-45.55% Debt Debt-to-Equity RatioN/A Current Ratio14.40 Quick Ratio14.40 Sales & Book Value Annual Sales$210,000.00 Price / Sales406.98 Cash FlowN/A Price / Cash FlowN/A Book Value$0.75 per share Price / Book3.56Miscellaneous Outstanding Shares32,010,000Free Float24,773,000Market Cap$85.47 million OptionableOptionable Beta0.84 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Amit Kumar Ph.D. (Age 60)CEO, Chairman & Co-Chair of CBAB Comp: $1.29MMr. Michael J. Catelani CPA (Age 57)MBA, President, COO, CFO & Corporate Secretary Comp: $788.83kMr. John Roop (Age 74)Senior Vice President of Engineering Comp: $275kDr. Pamela D. Garzone Ph.D. (Age 69)Chief Development Officer & Chair Breast Cancer Clinical Advisory Board Key CompetitorsEnzo BiochemNYSE:ENZPsychemedicsNASDAQ:PMDEmergent BioSolutionsNYSE:EBSSilverback TherapeuticsNASDAQ:SBTXAlto NeuroscienceNYSE:ANROView All CompetitorsInsiders & InstitutionsLewis H Titterton JrBought 10,738 shares on 6/7/2024Total: $27,059.76 ($2.52/share)Amit KumarBought 25,000 shares on 6/7/2024Total: $60,250.00 ($2.41/share)Michael CatelaniBought 6,250 shares on 6/7/2024Total: $15,000.00 ($2.40/share)Virtu Financial LLCBought 5,183 shares on 5/20/2024Ownership: 0.051%Staley Capital Advisers Inc.Bought 10,000 shares on 5/6/2024Ownership: 0.031%View All Insider TransactionsView All Institutional Transactions ANIX Stock Analysis - Frequently Asked Questions Should I buy or sell Anixa Biosciences stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Anixa Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANIX shares. View ANIX analyst ratings or view top-rated stocks. What is Anixa Biosciences' stock price target for 2024? 1 Wall Street research analysts have issued 12 month price targets for Anixa Biosciences' shares. Their ANIX share price targets range from $7.00 to $7.00. On average, they predict the company's share price to reach $7.00 in the next year. This suggests a possible upside of 162.2% from the stock's current price. View analysts price targets for ANIX or view top-rated stocks among Wall Street analysts. How have ANIX shares performed in 2024? Anixa Biosciences' stock was trading at $3.88 at the beginning of the year. Since then, ANIX stock has decreased by 31.2% and is now trading at $2.67. View the best growth stocks for 2024 here. Are investors shorting Anixa Biosciences? Anixa Biosciences saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 554,300 shares, a drop of 12.3% from the April 30th total of 632,100 shares. Based on an average daily trading volume, of 111,000 shares, the days-to-cover ratio is presently 5.0 days. Approximately 1.8% of the company's shares are sold short. View Anixa Biosciences' Short Interest. When is Anixa Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, September 4th 2024. View our ANIX earnings forecast. How were Anixa Biosciences' earnings last quarter? Anixa Biosciences, Inc. (NASDAQ:ANIX) posted its quarterly earnings results on Tuesday, June, 4th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.01. What other stocks do shareholders of Anixa Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Anixa Biosciences investors own include Cronos Group (CRON), Innovative Industrial Properties (IIPR), Roku (ROKU), Ally Financial (ALLY), Albireo Pharma (ALBO), Air Lease (AL), Akoustis Technologies (AKTS), Akero Therapeutics (AKRO), Aimmune Therapeutics (AIMT) and Advanced Emissions Solutions (ADES). Who are Anixa Biosciences' major shareholders? Anixa Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Virtu Financial LLC (0.05%), Simplicity Wealth LLC (0.04%), Staley Capital Advisers Inc. (0.03%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Amit Kumar, Arnold M Baskies, Lewis H Titterton Jr and Michael Catelani. View institutional ownership trends. How do I buy shares of Anixa Biosciences? Shares of ANIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ANIX) was last updated on 6/11/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | SponsoredDON’T buy gold until you read thisIf you're an American who understands that your money is rotting away as you read this email… Then this is ...Sasco Gold LLC | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anixa Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anixa Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.